UVD Robots Deploys Largest Fleet of Autonomous Disinfection Robots to a U.S. School District
26.3.2021 16:15:00 EET | Business Wire | Press release
Blue Ocean Robotics, the manufacturer of the autonomous disinfecting robot UVD Robots equipped with UV-C light, has been selected by Gallup McKinley County Schools (GMCS) in New Mexico to supply 37 UVD Robots to the districts’ schools to help fight the Coronavirus and other infectious diseases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210326005133/en/
Students from GMCS’ Twin Lakes School participated in a naming contest for the robot to help with socialization and morale. The school’s robot will now be known as Mr. Fox. UVD Robots were originally developed to fight Hospital Acquired Infections (HAI’s) and are now deployed in more than 60 countries worldwide in the healthcare sector, the hospitality industry, office complexes and educational facilities, meeting new and heightened expectations for safety and cleanliness. (Photo: Business Wire)
“COVID has taken an extraordinary toll on our community. The safety of our students and staff, developing a plan to bring them all back to school as safely as possible is our primary concern,” said Gallup McKinley Superintendent Michael Hyatt. “We wanted a larger, longer-term disinfection solution, adding a layer of protection that would disinfect surfaces and the air in our buildings and help fight COVID, colds, flu and infectious diseases for years to come.”
GMCS covers a community with many rural areas facing infrastructure issues that make virtual learning a challenge, approximately 1,500 students have no internet at home. The district also educates many special education students who learn better in the classroom.
“Unlike stationary disinfection robots, the UVD Robot is a fully autonomous robot. It integrates UV-C light to disinfect against viruses and bacteria on surfaces and the air, killing 99.99 percent of microorganisms within approximately 10 minutes in every room it disinfects,” said Claus Risager, CEO, Blue Ocean Robotics.
“We selected UVD Robots after rigorous review of numerous disinfecting robots,” said Hyatt. “UVD Robots delivered on all of our requirements including technical excellence, maturity and track record, quality of deployment, technical support and maintenance, and overall value.”
“We are excited to announce, what we believe is the largest deployment of autonomous disinfection robots in any U.S. school district,” said Per Juul Nielsen, CEO, UVD Robots. “We are honored to work with GMCS to go beyond COVID, bringing hospital-grade disinfection to the school district.”
About
UVD Robots is part of one of the world's leading groups in development of service robots, Blue Ocean Robotics, that includes brands GoBe Robots and PTR Robots. Blue Ocean Robotics is headquartered in Denmark and was recently included on Fast Company’s Top 10 of ‘Most Innovative Robotics Companies 2021.’
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210326005133/en/
Contact information
Camilla Almind Knudsen, Blue Ocean Robotics
+45 61 10 02 74
cak@blue-ocean-robotics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom